Thousands of cases of amputation and vision loss could be prevented thanks to diabetes monitoring technology. 

Continuous Glucose Monitors, or CGMs, have been funded for Type 1 diabetes since last October. 

New data from CGM producer Dexcom finds lifetime use of the devices could prevent up to 70 thousand diabetes-related complications and save the country $50 thousand a day. 

Diabetes New Zealand Chief Executive Heather Verry told Mike Hosking funding should be expanded to all diabetes patients. 

She says Pharmac is only funding for Type 1, and at $200 a month, these devices are unaffordable for everyone else. 

LISTEN ABOVE